Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL755487 | 0.87 | KMT2A (0.39) | ALDH1A1KMT2AHSD11B1CHRM1 | |
| SCHEMBL16185829 | 0.83 | PAOX (0.48) | ALDH1A1LMNASLC15A2ACHEPAOX | |
| SCHEMBL10017821 | 0.83 | ALDH1A1 (0.45) | ALDH1A1LMNASLC15A2TDP1ACHE | |
| SCHEMBL11253721 | 0.82 | ALDH1A1 (0.35) | ALDH1A1KMT2AHSD11B1 | |
| SCHEMBL15146906 | 0.81 | PAOX (0.52) | ALDH1A1LMNASLC15A2ACHEPAOX | |
| SCHEMBL18056080 | 0.81 | PAOX (0.52) | ALDH1A1LMNASLC15A2ACHEPAOX | |
| SCHEMBL16233152 | 0.78 | ALDH1A1 (0.32) | ALDH1A1TDP1KMT2A | |
| SCHEMBL24103118 | 0.78 | ALDH1A1 (0.40) | ALDH1A1LMNASLC15A2KMT2AGAA | |
| SCHEMBL10001 | 0.77 | — | — | |
| SCHEMBL409946 | 0.77 | EGLN1 (0.53) | LMNASLC15A2KMT2ACHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12595325-B2 | Process for the preparation of a multimodal polyethylene | BOREALIS AG (AT) | 2026-04-07 | — | — | US | disclosed |
| US-12583955-B2 | Metallocene complexes and catalysts made therefrom | BOREALIS AG (AT) | 2026-03-24 | — | — | US | disclosed |
| US-12319698-B2 | Proteasome activity enhancing compounds | Kineta, Inc. (US) | 2025-06-03 | — | — | US | disclosed |
| US-20250171481-A1 | METALLOCENE COMPLEXES AND CATALYSTS MADE THEREFROM | BOREALIS AG (AT) | 2025-05-29 | — | — | US | disclosed |
| CN-116194493-B | Metallocene complexes and catalysts prepared therefrom | 博里利斯股份公司 | 2025-04-22 | — | — | CN | disclosed |
| CN-112585132-B | Proteasome activity enhancing compounds | 优曼尼蒂公司 | 2025-02-28 | — | — | CN | disclosed |
| US-20240002560-A1 | PROCESS FOR THE PREPARATION OF A MULTIMODAL POLYETHYLENE | BOREALIS AG (AT) | 2024-01-04 | — | — | US | disclosed |
| US-11814391-B2 | Macrocyclic compounds for the treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230357199-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-20230322853-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PROLIFERATIVE DISEASES AND DISORDERS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2023-10-12 | — | — | US | disclosed |
| US-20100216915-A1 | Levulinic acid ester derivatives as reactive plasticizers and coalescent solvents | ARCHER-DANIELS-MIDLAND COMPANY (US) | 2010-08-26 | — | — | US | disclosed |
| US-20100179181-A1 | PHARMACEUTICAL FORMULATIONS OF BIODEGRADABLE BIOCOMPATIBLE CAMPTOTHECIN-POLYMER CONJUGATES | MERSANA THERAPEUTICS, INC. (US) | 2010-07-15 | — | — | US | disclosed |
| US-7695863-B2 | rechargeable batteries having excellent battery cycle properties, electrical capacity and storage characteristic during charging, comprising electrodes and a nonaqueous electrolytic solution containing a dicarbonyl compound as an additive | UBE INDUSTRIES, LTD. (JP) | 2010-04-13 | — | — | US | disclosed |
| CN-100566005-C | The lithium secondary battery of nonaqueous electrolyte solution and this solution of use | UBE INDUSTRIES (JP) | 2009-12-02 | — | — | CN | disclosed |
| US-7576175-B2 | Amino acid terminated diphenylurea derivatives; display high binding affinity, specificity, and stability; use in treating cancer, inflammatory diseases, and autoimmune diseases | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-08-18 | — | — | US | disclosed |
| US-20080102377-A1 | rechargeable batteries having excellent battery cycle properties, electrical capacity and storage characteristic during charging, comprising electrodes and a nonaqueous electrolytic solution containing a dicarbonyl compound as an additive | UBE INDUSTRIES, LTD (JP) | 2008-05-01 | — | — | US | disclosed |
| WO-2008031016-A2 | HETEROCYCLIC LIGANDS FOR INTEGRIN IMAGING AND THERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-03-13 | — | — | WO | disclosed |
| CN-101091283-A | Nonaqueous electrolytic solution and lithium secondary battery using the same | UBE INDUSTRIES (JP) | 2007-12-19 | — | — | CN | disclosed |
| US-20070015927-A1 | New phosphoramidite compounds | POSTECH FOUNDATION (KR) | 2007-01-18 | — | — | US | disclosed |
| US-20060019900-A1 | Alpha-4 beta-1 integrin ligands for imaging and therapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322853-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PROLIFERATIVE DISEASES AND DISORDERS | POLI, PCNA, POLH | ALDH1A1 3968/4885LMNA 487/4885SLC15A2 4194/4885 |
| US-20100216915-A1 | Levulinic acid ester derivatives as reactive plasticizers and coalescent solvents | EPM2A, ALAD, GABRD | ALDH1A1 635/4885LMNA 908/4885SLC15A2 1196/4885 |
| US-20100179181-A1 | PHARMACEUTICAL FORMULATIONS OF BIODEGRADABLE BIOCOMPATIBLE CAMPTOTHECIN-POLYMER CONJUGATES | PAICS, TK1, PKLR | ALDH1A1 925/4885LMNA 942/4885SLC15A2 680/4885 |
| US-20070015927-A1 | New phosphoramidite compounds | TYMP, POLRMT, POLI | ALDH1A1 4594/4885LMNA 3045/4885SLC15A2 3641/4885 |
| US-12319698-B2 | Proteasome activity enhancing compounds | PSMG3, PSME3, PSMC4 | ALDH1A1 3438/4885LMNA 1575/4885SLC15A2 3957/4885 |
| US-12583955-B2 | Metallocene complexes and catalysts made therefrom | OPRM1, NR4A1, RRM1 | ALDH1A1 941/4885LMNA 1872/4885SLC15A2 3115/4885 |
| US-20060019900-A1 | Alpha-4 beta-1 integrin ligands for imaging and therapy | ITGA4, ITGB4, ITGA1 | ALDH1A1 1238/4885LMNA 2391/4885SLC15A2 1765/4885 |
| US-20230357199-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | CFD, TFPI, CFH | ALDH1A1 2338/4885LMNA 2135/4885SLC15A2 2273/4885 |
| US-12595325-B2 | Process for the preparation of a multimodal polyethylene | OPRM1, SIGMAR1, GPS1 | ALDH1A1 3615/4885LMNA 1361/4885SLC15A2 3515/4885 |
| US-20250171481-A1 | METALLOCENE COMPLEXES AND CATALYSTS MADE THEREFROM | OPRM1, NR4A1, POLM | ALDH1A1 1657/4885LMNA 1437/4885SLC15A2 2466/4885 |
| US-11814391-B2 | Macrocyclic compounds for the treatment of medical disorders | CFD, TFPI, CFH | ALDH1A1 4659/4885LMNA 816/4885SLC15A2 3491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.